Hims & Hers Health, Inc.
$14.60-$1.42 (-8.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $6.5B
- P/E
- 50.5x
- EV / EBITDA
- 46.1x
- Revenue
- $2.3B
- Net margin
- 5.5%
- ROCE
- 6.0%
Price chart
Technical chartScreen technicals →-56.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -50.0%
- 3M
- -54.2%
- 6M
- -36.6%
- 1Y
- -56.6%
- 5Y
- +99.7%
52-week range
Day change -$1.42 (-8.9%) from $16 to $15 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in HIMS, bought on each weekday since 2021.
News & filings
What Hims & Hers Health filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthRevenue grew 59.0% in fiscal 2025.
Concerns (1)
- The price is 44.8% below its 200-day average.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
Read moreShow less
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
- Sector
- Healthcare
- Shares outstanding
- 225.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $6.5B
- P/E
- 50.5x
- P/B
- 12.0x
- EV / EBITDA
- 46.1x
- EV / Sales
- 3.1x
- P/S
- 2.8x
- 52-week high
- $40.02
- 52-week low
- $14.52
Profitability
- Operating margin
- 4.5%
- Net margin
- 5.5%
- EBITDA margin
- 6.8%
- ROE
- 23.7%
- ROCE
- 6.0%
- ROIC
- 7.4%
- ROA
- 6.0%
- Asset turnover
- 1.09
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $2.3B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 59.0%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 64.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $57.4M
Solvency
- Current ratio
- 1.90
- Debt / Equity
- 2.07
- Debt / Assets
- 0.52
- CFO / Net profit
- 2.34
- Cash / Market cap
- 3.5%
Where the revenue went
Of every $100 of FY2025 revenue, $5 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $614.3M |
| Revenue | Gross profit | $1.7B |
| Gross profit | Research and development | $149.3M |
| Gross profit | Selling, general and administrative | $1.2B |
| Gross profit | Other operating expenses | $286.4M |
| Gross profit | Operating income | $105.6M |
| Operating income | Pretax income | $105.6M |
| Interest and other income | Pretax income | $18.3M |
| Pretax income | Net income | $123.9M |
| Tax benefit and other | Net income | $4.4M |
Revenue and net profit
Revenue grew 59.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $526.9M | -$65.7M |
| FY2023 | $872.0M | -$23.5M |
| FY2024 | $1.5B | $126.0M |
| FY2025 | $2.3B | $128.4M |
Cash flows
FY2025: $300.0M from operations, $57.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$26.5M | -$33.8M |
| FY2023 | $73.5M | $47.0M |
| FY2024 | $251.1M | $198.3M |
| FY2025 | $300.0M | $57.4M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $2.3B+59.0%1Y
- EBITDA
- $160.1M+102.7%1Y
- Net profit
- $128.4M+1.8%1Y
- Cash from operations
- $300.0M+19.5%1Y
- Free cash flow
- $57.4M-71.1%1Y
- Revenue CAGR, 3Y
- 64.5%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.3B | $160.1M | $128.4M | $57.4M | 23.7% | +59.0% | +1.8% |
Monthly returns
Month-by-month returns of HIMS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.2B |
| Current assets | $767.6M |
| Non-current assets | $1.4B |
| Liabilities | $1.6B |
| Current liabilities | $404.4M |
| Non-current liabilities | $1.2B |
| Equity | $540.9M |
| Paid-in capital | $652.4M |
| Retained earnings | -$113.8M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; HIMS highlighted.
P/E against peers
HIMS trades at 50.5x earnings against a peer median of -26.8x.
Not shown (no positive earnings and no EV / Sales): Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Immunovant, Inc., Terns Pharmaceuticals, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Hims & Hers Health, Inc.HIMSthis company | $6.5B | 50.5x | 12.0x | 23.7% | 46.1x |
| Apogee Therapeutics, Inc.APGE | $6.9B | -26.8x | 7.6x | -28.3% | -23.7x |
| Spyre Therapeutics, Inc.SYRE | $6.8B | — | 9.5x | -21.7% | — |
| Arcellx, Inc.ACLX | $6.7B | -29.4x | 16.7x | -56.9% | -30.2x |
| Immunovant, Inc.IMVT | $6.7B | -13.3x | 7.9x | -59.3% | -10.9x |
| Lantheus Holdings, Inc.LNTH | $6.7B | 28.7x | 6.1x | 21.4% | 17.2x |
| Kymera Therapeutics, Inc.KYMR | $6.1B | — | 3.9x | -19.7% | — |
| Terns Pharmaceuticals, Inc.TERN | $6.1B | -63.6x | 6.1x | -9.6% | -51.0x |
| Rhythm Pharmaceuticals, Inc.RYTM | $6.0B | — | 22.3x | -74.8% | — |
| Peer median | — | -26.8x | 7.7x | -25.0% | -23.7x |
Year-to-date ROI
HIMS since 1 January, against earlier years.
Historical volatility
HIMS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -13.0% |
| FY2023 | -3.4% |
| FY2024 | 4.2% |
| FY2025 | 4.5% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $2.3B |
| Cost of revenueCost Of Revenue | $614.3M |
| Gross profitGross Profit | $1.7B |
| Operating expensesOperating Expense | $1.6B |
| Research and developmentResearch And Development | $149.3M |
| Selling, general and administrativeSelling General And Administration | $1.2B |
| Other operating expensesOther Operating Expenses | $286.4M |
| Total expensesTotal Expenses | $2.2B |
| Operating incomeOperating Income | $105.6M |
| Interest and other | |
| Pretax incomePretax Income | $123.9M |
| TaxTax Provision | -$4.4M |
| Net incomeNet Income | $128.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.2B |
| Current assetsCurrent Assets | $767.6M |
| Non-current assetsTotal Non Current Assets | $1.4B |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.6B |
| Current liabilitiesCurrent Liabilities | $404.4M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.2B |
| EquityTotal Equity Gross Minority Interest | $540.9M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $300.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $300.0M |
| Net income, continuing operationsNet Income From Continuing Operations | $128.4M |
| Depreciation and amortisationDepreciation And Amortization | $54.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $54.5M |
| Amortization of securitiesAmortization Of Securities | -$2.0M |
| Stock-based compensationStock Based Compensation | $135.2M |
| Deferred taxDeferred Tax | -$13.0M |
| Deferred income taxDeferred Income Tax | -$13.0M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | -$4.4M |
| Asset impairmentAsset Impairment Charge | $530.0k |
| Change in working capitalChange In Working Capital | -$29.2M |
| Other non-cash itemsOther Non Cash Items | $30.0M |
| Investing cash flowInvesting Cash Flow | -$1.0B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$1.0B |
| Capital expenditureCapital Expenditure | -$242.6M |
| Purchase of PP&EPurchase Of PPE | -$226.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$226.0M |
| AcquisitionsPurchase Of Business | -$145.2M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$145.2M |
| Purchase of investmentsPurchase Of Investment | -$745.8M |
| Sale of investmentsSale Of Investment | $108.7M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$637.1M |
| Purchase of intangiblesPurchase Of Intangibles | -$16.6M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$16.6M |
| Financing cash flowFinancing Cash Flow | $729.6M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $729.6M |
| Debt issuedIssuance Of Debt | $970.0M |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | $970.0M |
| Long-term debt issuedLong Term Debt Issuance | $970.0M |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | $970.0M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$90.0M |
| Common stock repurchasedCommon Stock Payments | -$90.0M |
| Share buybacksRepurchase Of Capital Stock | -$90.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $17.5M |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | -$167.9M |
| Change in cashChanges In Cash | $4.7M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 251.0% |
| Cash at the start of the yearBeginning Cash Position | $221.4M |
| Cash at the end of the yearEnd Cash Position | $228.6M |
| Free cash flowFree Cash Flow | $57.4M |
| Supplemental |
Learn while you research
Academy chapters picked for Hims & Hers Health, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 50.5, learn when high multiples are justified.6 min read
- 03 Growth Investing59% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Leverage RatiosDebt/Equity of 2.07 is elevated, understand what that means for solvency.6 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read